• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
Addiction Treatment Forum

Addiction Treatment Forum

Addiction Treatment Forum reports on substance use news of interest to opioid treatment programs and patients in medication-assisted treatment.

  • Newsletter
  • Addiction Resources
  • Methadone
  • Buprenorphine
  • Patient Brochures
  • Events

OTPs Can Now Dispense Buprenorphine Take-Homes with No Waiting Periods

February 12, 2013 by ATForum

As of January 7, 2013, opioid treatment programs (OTPs) can now dispense buprenorphine take-homes, with no predetermined waiting period for stable patients. The Substance Abuse and Mental Health Services Administration (SAMHSA) at last issued its final rule giving OTPs the welcome flexibility this past November, and the rule was published in the Federal Register December 6, 2012. Fears of diversion were probably the driving force behind the delay in the final rule; the proposed rule was issued in June 2009.

Because Schedule III substances—like buprenorphine—have a lower potential for abuse compared to Schedule II substances—like methadone—there is justification for the less-restrictive rules on dispensing buprenorphine, according to SAMHSA.

Of course, states can have stricter rules. Some require OTPs to be open 7 days a week, and the idea of buprenorphine take-homes isn’t even on their radar screens. Still, the final rule is a very important first step for OTPs and their patients.

Most OTP physicians (80 percent) have already completed the DATA training and obtained the required waivers, according to SAMHSA. OTPs will not have a cap on how many patients they can treat with either buprenorphine or methadone. However, for take-homes, OTPs will still be “required to assess and document each patient’s responsibility and stability to handle opioid drug products, including buprenorphine products,” SAMHSA said in the final rule.

At this important juncture in the history of OTPs, accompanying articles in this issue take a look back at the development of buprenorphine and methadone for treating patients with opioid use disorders, and the differences between the two medications. We also report thoughts from leaders in the field as to what the new rule is likely to mean to OTPs and their patients.

Filed Under: 2013, 23-1, Newsletter

Primary Sidebar

Upcoming Events

AMERSA’s Annual Conference
November 2-4, 2023

AMERSA’s annual conference will be held November 2-4 in Washington, DC. For more information, go to https://amersa.org/2023-conference/

The American Academy of Addiction Psychiatry Annual Symposium
December 7-10, 2023

The American Academy of Addiction Psychiatry annual symposium will be held December 7-10 in San Diego. For more information, go to https://www.aaap.org/training-events/annual-meeting/2023-annual-meeting/

The 2024 AATOD Conference
May 18-22, 2024

The 2024 AATOD conference will be held May 18-22 in Las Vegas. For more information, go to https://aatod.eventscribe.net/

 

View More Upcoming Events…

ATForum.com

  • Newsletter
  • Addiction Resources
  • Rx Methadone & Safety
  • Patient Education Brochures
  • Events
  • Related Websites

Addiction Resources

  • Addiction and Recovery
  • Addiction Treatment Forum
  • Books and Booklets of Interest
  • Drug Screening and Testing
  • Evidence-Based Addiction Medicine
  • Federal Government
  • Health Care Reform
  • Hepatitis, HIV/AIDS
  • Medication-Assisted Treatment
  • Mental Health
  • Miscellaneous
  • Online Continuing Education Free Training Modules

Footer

Addiction Treatment Forum is produced by an independent medical communications agency. Commercial advertising is not accepted.
Published by Clinco Communications, Inc. & Communication Clinco, NFP.
About Us
Contact Us
Privacy Policy
Terms of Use
Follow Us

Sign up for News!

© 2023 Addiction Treatment Forum · All Rights Reserved